Welcome to our dedicated page for IQVIA HOLDINGS SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
Harris Associates L.P. and Harris Associates, Inc. filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership of IQVIA Holdings Inc. common stock. The filing shows an aggregate of 11,753,182 shares, representing 6.8% of the class, with sole voting power over 10,291,782 shares and sole dispositive power over 11,753,182 shares. The Schedule identifies IQVIA's principal executive office at 2400 Ellis Road, Durham, NC.
The statement notes the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is dated as an event on 06/30/2025 and signed on 08/14/2025 by Joseph J. Allessie as General Counsel and Secretary.
IQVIA Holdings Inc. (IQV) filed a Form 4 showing that Senior Vice President & Corporate Controller Keriann Cherofsky sold 549 common shares on 07/23/2025 at $191.53 per share, a transaction valued at roughly $105k. After the sale, her direct ownership stands at 2,910 shares; no derivative securities were involved.
The disposition reduced her direct stake by about 16% (549 of ~3,459 prior shares). While small relative to IQV’s market capitalization and daily trading volume, insider sales can be perceived as a modestly bearish signal because executives possess superior insight into company prospects. No accompanying purchases, option exercises, or material company events were reported in this filing.
IQVIA Holdings Inc. (IQV) – Form 144 filing discloses a proposed insider sale of common stock under Rule 144.
- Securities offered: 5,800 common shares
- Estimated market value: $1,102,262.16 (≈ $190 per share)
- Broker: Morgan Stanley Smith Barney LLC, New York
- Planned sale date: 23 Jul 2025 on the NYSE
- Total shares outstanding: 170 million; proposed sale equals <0.01% of float
- Source of shares: Stock Appreciation Rights acquired on 23 Jul 2025; consideration paid in cash
The filer states no material non-public adverse information is known. No other sales were made in the past three months. Given the small size relative to IQVIA’s float and the absence of accompanying operational data, the notice is unlikely to affect valuation or liquidity materially.